2024-11-27 - Analysis Report
## Vertex Pharmaceuticals Inc (VRTX) Stock Analysis Report

**1. Performance Relative to S&P 500 (VOO):**

Vertex Pharmaceuticals Inc. (VRTX) is a biotechnology company focused on the discovery, development, and commercialization of innovative medicines.  The cumulative return for VRTX is 172.99%, significantly outperforming the S&P 500 (VOO) with a cumulative return of 128.31%. The difference is 44.7%, placing it at the 69.9th percentile of its historical performance relative to the S&P 500 based on the provided data.  This indicates strong relative performance, but the relative strength is not a guarantee of future outperformance.

**Alpha and Beta Analysis:**

The provided data shows varying alpha and beta values over different time periods.  Alpha, a measure of excess return relative to the market (beta), reveals periods of significant outperformance (high positive alpha) and periods of closer alignment with market performance (lower alpha). Beta, a measure of volatility relative to the market, shows that VRTX is generally more volatile than the market (beta consistently > 1).  This higher volatility contributes to the significant swings observed in its performance relative to the S&P 500.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 6.8% | 32.2% | -4.7% | 3.3 | 38.6 |
| 2016-2018  | 10.5% | 31.5% | 0.7% | 3.0 | 42.7 |
| 2017-2019  | 43.0% | 19.1% | 28.1% | 2.6 | 56.4 |
| 2018-2020  | 15.6% | 30.4% | 1.8% | 1.6 | 60.9 |
| 2019-2021  | 10.2% | 34.7% | -15.8% | 1.5 | 56.6 |
| 2020-2022  | 9.6% | 34.7% | 2.3% | 1.4 | 74.4 |
| 2021-2023  | 21.0% | 21.3% | 10.5% | 1.6 | 104.8 |
| 2022-2024  | 27.5% | 18.8% | 18.3% | 1.5 | 116.1 |


**2. Recent Price Movement:**

* **Closing Price:** 461.71 (Last Market: 465.46)
* **5-Day Moving Average:** 452.46
* **20-Day Moving Average:** 477.17
* **60-Day Moving Average:** 473.99

The price is currently below its 20-day and 60-day moving averages, suggesting a short-term downtrend.

**3. Technical Indicators:**

* **RSI (34.77):**  Indicates the stock is currently in oversold territory, suggesting potential for a price bounce.
* **PPO (-0.89):** Negative value suggests bearish momentum.
* **20-Day Relative Divergence (-9.4%):** Shows a recent downward trend in relative strength.

The last market price (465.46) being higher than the closing price (461.71) indicates a small price drop, but not a sharp decline.
* **Expected Return (79.6%):** This represents the projected long-term (2+ years) excess return compared to the S&P 500, assuming continued strong performance.  This is a high projection and should be viewed cautiously.


**4. Recent Financial Performance:**

The EPS figures are volatile, with significant swings between positive and negative values.  Revenue shows consistent growth, but profitability fluctuates.  Further analysis, including comparing these figures to expectations and industry benchmarks, would be necessary for a complete assessment.


| Date       | EPS     | Revenue       |
|------------|---------|---------------|
| 2024-11-05 | 4.05    | 2.77 B$       |
| 2024-08-02 | -13.92  | 2.65 B$       |
| 2024-05-07 | 4.26    | 2.69 B$       |
| 2023-11-07 | 4.01    | 2.48 B$       |
| 2024-11-05 | 4.01    | 2.48 B$       |(Duplicate entry - likely a data entry error)


**6. Financial Information:**

**Revenue and Profitability:**  Profit margins are consistently high (above 85%), indicating strong profitability. Revenue is steadily increasing.

**Capital and Profitability:** ROE (Return on Equity) fluctuates, showing periods of both strong returns and losses. This volatility warrants further investigation into the underlying drivers.


**7. News and Recent Issues:**

*(This section requires access to real-time news sources like Shacknews and Finbold.  Please provide recent news articles for a more detailed analysis.)*  I need access to up-to-the-minute news sources to fulfill this part of the request.  The analysis would include a summary of recent earnings announcements, analyst opinions, and any market outlook changes affecting VRTX.


**8. Overall Summary:**

VRTX has demonstrated significant outperformance relative to the S&P 500 over the long term, supported by high profit margins. However, the stock exhibits considerable volatility and shows inconsistent earnings. The relatively high expected return should be viewed cautiously given the inherent risk associated with a volatile stock in the biotech sector.  Recent technical indicators suggest potential for a short-term price bounce, but further analysis of recent news and financial statements is crucial to make an informed investment decision.  The high level of volatility underscores the importance of a long-term investment strategy and a tolerance for significant price swings.


**9. Disclaimer:** This analysis is based solely on the provided data and publicly available information. It is not financial advice.  Independent research and consultation with a financial advisor are recommended before making any investment decisions.  The accuracy and completeness of the provided data are assumed, but should be independently verified.
